Skip to main content

Table 3 Life Table representation of cumulative incidence of crude therapeutic failure attributable to drug resistance among subjects treated with chloroquine (CQ) and CQ + sulfadoxine/pyrimethamine (SP) without distinguishing recrudescence from reinfection

From: Combined chloroquine, sulfadoxine/pyrimethamine and primaquine against Plasmodium falciparum in Central Java, Indonesia

CQ

CQ+SP

D

N

I

W

IR

CIF

D

N

I

W

IR

CIF

0

29

0

0

0.00

0.00

0

88

0

0

0.00

0.00

2

29

0

0

0.00

0.00

2

88

0

2

0.00

0.00

4

29

0

0

0.00

0.00

4

86

1

1

0.01

0.01

7

29

0

0

0.00

0.00

7

84

1

0

0.01

0.02

11

29

1

0

0.03

0.03

11

83

0

0

0.00

0.02

14

28

2

1

0.07

0.10

14

83

0

0

0.00

0.02

18

25

2

1

0.08

0.18

18

83

0

2

0.00

0.02

21

22

2

2

0.10

0.26

21

81

0

1

0.00

0.02

28

18

4

0

0.22

0.42

28

80

3

1

0.04

0.06

  1. N = sample at risk of therapeutic failure at start of interval
  2. i = the number of cases of therapeutic failure during the interval
  3. w = the number of subjects withdrawn from the test during the interval due to exclusion from analysis, loss to follow-up after latest blood smear, intercurrent infection with another plasmodia species, or reinfection by different genotype P. falciparum or relapse/reinfection by P. vivax based on day of recurrent parasitemia CQ +DCQ concentrations
  4. IR = risk of therapeutic failure in the interval, calculated as i/(N-w/2)
  5. CIF = cumulative incidence of therapeutic failure, calculated as 1-[(1-IRn)(1-CIFn-1)], where IRn is the IR in the current interval and CIFn-1 is the cumulative incidence up to the previous interval